GR3030369T3 - Transdermal drug delivery system - Google Patents

Transdermal drug delivery system

Info

Publication number
GR3030369T3
GR3030369T3 GR990401461T GR990401461T GR3030369T3 GR 3030369 T3 GR3030369 T3 GR 3030369T3 GR 990401461 T GR990401461 T GR 990401461T GR 990401461 T GR990401461 T GR 990401461T GR 3030369 T3 GR3030369 T3 GR 3030369T3
Authority
GR
Greece
Prior art keywords
therapeutic agent
pct
cyclodextrin
date jan
sec
Prior art date
Application number
GR990401461T
Other languages
English (en)
Inventor
Arto Olavi Urtti
Maria Riitta Sutinen
Timo Petteri Paronen
Original Assignee
Arto Olavi Urtti
Maria Riitta Sutinen
Timo Petteri Paronen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arto Olavi Urtti, Maria Riitta Sutinen, Timo Petteri Paronen filed Critical Arto Olavi Urtti
Publication of GR3030369T3 publication Critical patent/GR3030369T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR990401461T 1994-07-08 1999-05-28 Transdermal drug delivery system GR3030369T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9413866A GB2290964A (en) 1994-07-08 1994-07-08 Transdermal drug delivery system
PCT/FI1995/000358 WO1996001626A1 (en) 1994-07-08 1995-06-20 Transdermal drug delivery system

Publications (1)

Publication Number Publication Date
GR3030369T3 true GR3030369T3 (en) 1999-09-30

Family

ID=10758074

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401461T GR3030369T3 (en) 1994-07-08 1999-05-28 Transdermal drug delivery system

Country Status (12)

Country Link
US (1) US5817332A (el)
EP (1) EP0764020B1 (el)
JP (1) JP3734267B2 (el)
AT (1) ATE178485T1 (el)
AU (1) AU2740595A (el)
CA (1) CA2193129C (el)
DE (1) DE69508938T2 (el)
DK (1) DK0764020T3 (el)
ES (1) ES2130622T3 (el)
GB (1) GB2290964A (el)
GR (1) GR3030369T3 (el)
WO (1) WO1996001626A1 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0838225A3 (en) * 1996-10-25 1999-03-24 Hiji, Yasutake Aqueous local anesthetic solution
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DE19810951B4 (de) * 1998-03-13 2005-09-29 Ciba Speciality Chemicals Holding Inc. Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung
DE19814087A1 (de) 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
WO2001043775A2 (en) * 1999-12-16 2001-06-21 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6689378B1 (en) 1999-12-28 2004-02-10 Kimberly-Clark Worldwide, Inc. Cyclodextrins covalently bound to polysaccharides
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
PL373780A1 (en) * 2002-02-25 2005-09-19 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
PT1629844E (pt) 2004-07-13 2007-10-17 Bayer Schering Pharma Oy Sistema de distribuição a longo prazo com distribuição súbita inicial controlada
UA95903C2 (ru) * 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
US8287923B2 (en) * 2005-06-10 2012-10-16 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating immune disorders
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
BRPI0710674A2 (pt) * 2006-04-07 2011-08-23 Allergan Inc composições incluindo fármacos relativamente insolúveis em água/não umectáveis e métodos para usar as mesmas
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
JP2010524855A (ja) 2007-04-13 2010-07-22 ディフュージョン・ファーマシューティカルズ・エルエルシー 末梢血管疾患の前処置としての、及びその処置における双極性トランスカロテノイドの使用
BRPI0818119A2 (pt) * 2007-10-31 2015-08-04 Diffusion Pharmaceuticals Llc Uma nova classe de produtos terapêuticos que melhoram difusão de molécula pequena
EP2445339B1 (en) * 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
EP2459184A1 (en) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
EP2556082B1 (en) 2010-04-08 2017-02-22 Emory University Substituted androst-4-ene diones
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
WO2012129237A2 (en) 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
EP2704726B1 (en) 2011-05-04 2018-10-31 Trustees of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (en) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Compositions and Methods for Treating Herpes Simplex Virus
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
CA2924141C (en) 2013-08-22 2022-06-07 The General Hospital Corporation 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
EP3038625A4 (en) 2013-08-29 2017-08-23 Trustees of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
CA2924188C (en) * 2013-10-07 2018-12-18 Teikoku Pharma Usa, Inc. Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
ES2856189T3 (es) 2013-10-07 2021-09-27 Teikoku Pharma Usa Inc Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina
TW201609200A (zh) 2013-12-18 2016-03-16 丸石製藥股份有限公司 含水型貼劑
JP2017501224A (ja) * 2013-12-18 2017-01-12 ジー・エヌ・ティー・エル・エル・シー 緑内障の治療用組成物及び方法
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
WO2017017631A2 (en) 2015-07-28 2017-02-02 Vyome Biosciences Pvt. Ltd. Antibacterial therapeutics and prophylactics
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
KR20230014850A (ko) 2016-03-24 2023-01-30 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도
EP3562486B1 (en) 2016-12-31 2024-03-13 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
EP3813802A4 (en) 2018-06-27 2022-06-08 Bioxcel Therapeutics, Inc. FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM
TWI772807B (zh) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
EP4308088A1 (en) 2021-11-08 2024-01-24 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4749574A (en) * 1986-04-14 1988-06-07 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4781924A (en) * 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
CA2120748A1 (en) * 1991-10-16 1993-04-29 Arto Olavi Urtti Peroral drug delivery system
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation

Also Published As

Publication number Publication date
DK0764020T3 (da) 1999-10-18
ES2130622T3 (es) 1999-07-01
WO1996001626A1 (en) 1996-01-25
GB9413866D0 (en) 1994-08-24
ATE178485T1 (de) 1999-04-15
DE69508938D1 (de) 1999-05-12
CA2193129A1 (en) 1996-01-25
JP3734267B2 (ja) 2006-01-11
EP0764020A1 (en) 1997-03-26
CA2193129C (en) 2007-11-06
EP0764020B1 (en) 1999-04-07
AU2740595A (en) 1996-02-09
DE69508938T2 (de) 1999-09-16
GB2290964A (en) 1996-01-17
US5817332A (en) 1998-10-06
JPH10502388A (ja) 1998-03-03

Similar Documents

Publication Publication Date Title
GR3030369T3 (en) Transdermal drug delivery system
ATE298259T1 (de) Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
BR0010869A (pt) Método para administrar um corticosteróide a um segmento posterior de um olho e dispositivo de liberação sustentada implantável
MXPA02011624A (es) Uso de una composicion de celecoxib para alivio rapido del dolor.
TR200001998T1 (tr) Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
ES2007100A6 (es) Procedimiento para la obtencion de un sistema terapeutico oral a base de carbamazepina.
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
GB9313484D0 (en) Drug system ii
ES2158101T3 (es) Formulaciones farmaceuticas efervescentes que contienen microcapsulas biodegradables de liberacion controlada.
SG146638A1 (en) Pharmaceutical delivery system
IL140848A0 (en) Treatment regimen for administration of phenylacetylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate
WO2000013662A3 (en) Medicated chewing gum delivery system for nicotine
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
HK1038310A1 (en) Compositions and methods for treating intracellular infections.
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
ATE135203T1 (de) System zur peroralen arzneimittelabgabe
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
UA37510A (uk) Спосіб лікування загрози передчасного переривання вагітності
MD1568G2 (ro) Metodă de tratament al bolii arşilor în perioada şocului combustional
MY124346A (en) Medicated chewing gum delivery system for nicotine